Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
一项随机 II 期试验，旨在评估阿特珠单抗联合卡培他滨辅助治疗与卡培他滨单药治疗在接受新辅助化疗后仍有残留浸润性癌的三阴性乳腺癌中的疗效和安全性（MIRINAE 试验，KCSG-BR18-21）。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14673-0
Lee, Jieun; Ahn, Hee Kyung; Lee, Kyung-Hun; Jung, Kyung Hae; Park, Yeon Hee; Sim, Sung Hoon; Kim, Min Hwan; Kim, Jee Hyun; Kim, Jee Hung; Lee, Kyoung Eun; Park, Kyong Hwa; Bae, Jihong; Lee, Moon Hee; Lim, Seungtaek; Kim, Han Jo; Lee, Dae-Won; Jeong, Jae Ho; Kim, Ji-Yeon; Ahn, Jin Seok; Lee, Keun Seok; Sohn, Joohyuk; Suh, Koung Jin; Cha, Yoon Jin; Shin, Kabsoo; Kim, Sung-Bae; Chae, Heejung; Kim, Gun Min; Im, Seock-Ah; Park, In Hae
